\-\ Texto\\:\\ \ \(0\)\
\-\ h\\/h\\:\\ 13\\.1\\/39\\.5\\ \\(low\\)\ \(0\)\
\-\ chem\\ panel\\ normal\ \(0\)\
\-\ lfts\\ normal\ \(0\)\
\-\ amylase\\/lipase\\ normal\ \(1\)\
\-\ patient\\ received\\ an\\ egd\\ which\\ demonstrated\\ a\\ large\\,\\ fungating\\ mass\\ in\\ the\\ lower\\ third\\ of\\ the\\ esophagus\\.\\ the\\ mass\\ was\\ partially\\ obstructing\\ and\\ circumferential\\ involving\\ two\\ thirds\\ of\\ the\\ lumen\\.\\ this\\ mass\\ appeared\\ to\\ extend\\ to\\ the\\ gastric\\ cardia\\.\\ multiple\\ biopsies\\ were\\ obtained\\.\\ \ \(0\)\
\-\ a\\ malignant\\ esophageal\\ tumor\\ was\\ suspected\\ and\\ patient\\ subsequently\\ received\\ an\\ iv\\-contrast\\ enhanced\\ ct\\ of\\ the\\ chest\\,\\ abdomen\\,\\ and\\ pelvis\\ to\\ evaluate\\ for\\ any\\ metastatic\\ disease\\.\\ a\\ pet\\ scan\\ obtained\\ after\\ the\\ ct\\ test\\ did\\ not\\ show\\ evidence\\ of\\ lymphatic\\ or\\ hematogenous\\ metastases\ \(0\)\
\-\ iv\\ contrast\\ ct\\ of\\ chest\\,\\ abd\\,\\ pelvis\\:\ \(0\)\
\-\ a\\ 6\\.1x4\\.5cm\\ mass\\ that\\ extended\\ into\\ the\\ proximal\\ portion\\ of\\ the\\ stomach\\ was\\ noted\\ at\\ the\\ gatroesophageal\\ junction\\.\\ there\\ does\\ not\\ appear\\ to\\ be\\ any\\ obstruction\\ of\\ fluids\\ as\\ contrast\\ has\\ advanced\\ through\\ the\\ lesion\\ and\\ into\\ the\\ distal\\ bowel\\.\\ \ \(0\)\
\-\ there\\ is\\ a\\ 1\\.9cm\\ rounded\\ lesion\\ near\\ the\\ tail\\ of\\ the\\ pancreas\\ and\\ a\\ 1\\.0cm\\ enlarged\\ lymph\\ node\\ adjacent\\ to\\ the\\ portal\\ vein\\ that\\ is\\ concerning\\ for\\ metastatic\\ disease\\ and\\ \\ should\\ be\\ further\\ evaluated\\ by\\ a\\ pet\\ scan\\.\\ \ \(0\)\
\-\ there\\ are\\ multiple\\ hypodensities\\ in\\ the\\ liver\\ and\\ left\\ kidney\\ that\\ are\\ too\\ small\\ to\\ characterize\\ but\\ should\\ be\\ further\\ evaluated\\.\ \(0\)\
\-\ adenocarcinoma\ \(192\)\
\-\ lymphoma\ \(373\)\
\-\ metastatic\\ disease\ \(243\)\
\-\ 2\\ week\\ h\\/o\\ of\\ dysphagia\\ to\\ solids\\ and\\ hematemesis\ \(1\)\
\-\ pmh\\:\\ htn\ \(0\)\
\-\ psh\\:\\ none\ \(0\)\
\-\ meds\\:\\ atenolol\ \(0\)\
\-\ all\\:\\ carbamazepine\ \(0\)\
\-\ sh\\:\\ no\\ tobacco\\ or\\ etoh\\ use\ \(0\)\
\-\ esophageal\\ cancer\\ is\\ the\\ 10th\\ leading\\ cause\\ of\\ deaths\\ due\\ to\\ cancer\\ in\\ the\\ united\\ states\\ and\\ continues\\ to\\ be\\ the\\ 19th\\ among\\ cancers\\ in\\ incidence\\.\\ the\\ two\\ main\\ types\\ are\\ squamous\\ cell\\ carcinoma\\ and\\ adenocarcinoma\\.\\ although\\ squamous\\ cell\\ constitutes\\ 95\\%\\ of\\ esophageal\\ cancers\\ worldwide\\,\\ adenocarcinoma\\ has\\ steadily\\ increased\\ to\\ be\\ the\\ major\\ histological\\ type\\ in\\ the\\ us\\ since\\ the\\ 1970s\\.\ \(0\)\
\-\ adenocarcinoma\\ affects\\ white\\ males\\ in\\ the\\ 6th\\ or\\ 7th\\ decade\\ and\\ is\\ most\\ commonly\\ located\\ in\\ the\\ distal\\ esophagus\\.\\ \\ risk\\ factors\\ include\\ gastroesophageal\\ reflux\\ disease\\ and\\ barrett\\‚\\Ä\\ôs\\ esophagus\\ where\\ there\\ is\\ replacement\\ of\\ normal\\ squamous\\ lining\\ with\\ intestinal\\-type\\ columnar\\ epithelium\\.\\ \\ interestingly\\,\\ these\\ histological\\ changes\\ were\\ found\\ in\\ patients\\ without\\ reflux\\ symptoms\\.\\ in\\ a\\ swedish\\ population\\-based\\ study\\,\\ 40\\%\\ of\\ patients\\ with\\ cancer\\ did\\ not\\ have\\ symptoms\\ at\\ least\\ weekly\\.\\ \\ in\\ comparison\\,\\ squamous\\ cell\\ cancer\\ of\\ esophagus\\ is\\ located\\ in\\ proximal\\-mid\\ esophagus\\,\\ affects\\ black\\ males\\,\\ and\\ is\\ commonly\\ associated\\ with\\ tobacco\\ and\\ alcohol\\ consumption\\.\\ \ \(0\)\
\-\ common\\ presenting\\ symptoms\\ of\\ esophageal\\ cancer\\ are\\ dysphagia\\,\\ weight\\ loss\\,\\ gerd\\ odynophagia\\,\\ and\\ dyspnea\\.\\ these\\ symptoms\\,\\ especially\\ any\\ evidence\\ of\\ mechanical\\ obstruction\\,\\ should\\ prompt\\ an\\ upper\\ endoscopy\\ where\\ biopsies\\ can\\ be\\ obtained\\.\\ the\\ primary\\ tumor\\ can\\ then\\ be\\ imaged\\ suing\\ ct\\ and\\ endoscopic\\ ultrasound\\.\\ ct\\ provides\\ a\\ general\\ overview\\ of\\ the\\ cancer\\ and\\ demonstrates\\ adjacent\\ organ\\ involvement\\,\\ although\\ esophageal\\ wall\\ layers\\ are\\ not\\ easily\\ distinguished\\.\\ eus\\ is\\ gaining\\ popularity\\ due\\ to\\ its\\ strength\\ in\\ visualizing\\ the\\ wall\\ layers\\.\\ its\\ drawbacks\\ include\\ operator\\ skill\\ and\\ viewing\\ \\‚\\Ä\\úhard\\ to\\ reach\\‚\\Ä\\ù\\ tumors\\.\\ \ \(0\)\
\-\ once\\ the\\ diagnosis\\ of\\ the\\ tumor\\ is\\ made\\,\\ imaging\\ to\\ rule\\ out\\ metastatic\\ disease\\ should\\ be\\ performed\\.\\ intravenous\\-contrast\\ enhanced\\ ct\\ of\\ the\\ chest\\,\\ abdomen\\,\\ and\\ pelvis\\ remains\\ the\\ gold\\ standard\\ although\\ sensitivity\\ is\\ dependent\\ on\\ the\\ size\\ of\\ the\\ lesion\\.\\ mri\\ and\\ us\\ modalities\\ can\\ be\\ used\\ to\\ further\\ characterize\\ metastatic\\ lesions\\.\\ positron\\ emission\\ tomography\\ is\\ a\\ new\\ tool\\ that\\ visualizes\\ the\\ higher\\ rate\\ of\\ glucose\\ uptake\\ by\\ malignant\\ tissue\\ versus\\ normal\\,\\ thus\\,\\ providing\\ more\\ information\\ about\\ metastatic\\ disease\\.\\ \ \(0\)\
\-\ appropriate\\ imaging\\ allows\\ clinicians\\ to\\ properly\\ stage\\ the\\ tumor\\,\\ which\\ directly\\ affects\\ the\\ treatment\\ options\\ and\\ prognosis\\.\\ well\\ localized\\ tumors\\ can\\ be\\ resected\\ and\\ have\\ the\\ best\\ 5\\-year\\ survival\\ of\\ 65\\-85\\%\\.\\ more\\ invasive\\ tumors\\ and\\ those\\ with\\ distant\\ metastses\\ are\\ not\\ surgical\\ candidates\\ and\\ are\\ treated\\ with\\ combined\\ chemotherapy\\ and\\ radiation\\ therapy\\ for\\ palliation\\.\\ the\\ overall\\ 5yr\\ survival\\ of\\ esophageal\\ cancer\\ is\\ 12\\-15\\%\\.\ \(0\)\
\-\ references\ \(24\)\
\-\ elton\\,\\ eric\\.\\ \\‚\\Ä\\úesophageal\\ cancer\\,\\‚\\Ä\\ù\\ disease\\-a\\-mouth\\,\\ v51\\,\\ n12\\ \\(2005\\)\\ 664\\-684\\.\ \(0\)\
\-\ korst\\,\\ r\\ and\\ altorki\\,n\\.\\ \\‚\\Ä\\úimaging\\ for\\ esophageal\\ tumors\\,\\‚\\Ä\\ù\\ radiologic\\ clinics\\ of\\ north\\ america\\ 43\\(2005\\)\\ 611\\-619\\.\ \(0\)\
\-\ patel\\,\\ a\\ and\\ buenaventura\\,\\ p\\.\\ \\‚\\Ä\\úcurrent\\ staging\\ of\\ esophageal\\ carcinoma\\,\\‚\\Ä\\ù\\ surgical\\ clinics\\ of\\ north\\ america\\ 85\\ \\(2005\\)\\ 555\\-567\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ the\\:\\ 0\\.270889508374426\ \(0\)\
\-\ esophageal\\:\\ 0\\.26768793333223484\ \(0\)\
\-\ and\\:\\ 0\\.19421342563604901\ \(0\)\
\-\ cancer\\:\\ 0\\.18548813164258152\ \(0\)\
\-\ of\\:\\ 0\\.17711696278358502\ \(0\)\
\-\ esophagus\\:\\ 0\\.14333471074764056\ \(0\)\
\-\ be\\:\\ 0\\.14121083315461808\ \(0\)\
\-\ to\\:\\ 0\\.1305370099771806\ \(0\)\
\-\ squamous\\:\\ 0\\.12530694887685817\ \(0\)\
\-\ metastatic\\:\\ 0\\.11454973198166013\ \(0\)\
\-\ is\\:\\ 0\\.11439592939717337\ \(0\)\
\-\ adenocarcinoma\\:\\ 0\\.11380616799353693\ \(0\)\
\-\ affects\\:\\ 0\\.10701193376825305\ \(0\)\
\-\ in\\:\\ 0\\.10391560566753946\ \(0\)\
\-\ tumors\\:\\ 0\\.10240427227211141\ \(0\)\
\-\ disease\\:\\ 0\\.10228442926348946\ \(0\)\
\-\ 2005\\:\\ 0\\.09924683960712131\ \(0\)\
\-\ are\\:\\ 0\\.09246206235688006\ \(0\)\
\-\ should\\:\\ 0\\.09085446404054848\ \(0\)\
\-\ characterize\\:\\ 0\\.08758866301834432\ \(0\)\
\-\ clinics\\:\\ 0\\.08758866301834432\ \(0\)\
\-\ america\\:\\ 0\\.08207230146647342\ \(0\)\
\-\ north\\:\\ 0\\.08051212822492215\ \(0\)\
\-\ ct\\:\\ 0\\.0795152892231688\ \(0\)\
\-\ biopsies\\:\\ 0\\.07912898092756328\ \(0\)\
\-\ histological\\:\\ 0\\.07675935698008254\ \(0\)\
\-\ layers\\:\\ 0\\.07675935698008254\ \(0\)\
\-\ symptoms\\:\\ 0\\.07618455311222176\ \(0\)\
\-\ cancers\\:\\ 0\\.07477585547297898\ \(0\)\
\-\ tobacco\\:\\ 0\\.07389320050053236\ \(0\)\
\-\ obtained\\:\\ 0\\.07386779333477816\ \(0\)\
\-\ can\\:\\ 0\\.07306904066870325\ \(0\)\
\-\ pelvis\\:\\ 0\\.07303927583931955\ \(0\)\
\-\ tumor\\:\\ 0\\.07283089748418317\ \(0\)\
\-\ males\\:\\ 0\\.07181076018895328\ \(0\)\
\-\ although\\:\\ 0\\.07109423524847046\ \(0\)\
\-\ normal\\:\\ 0\\.07106373954511874\ \(0\)\
\-\ not\\:\\ 0\\.0687110817290926\ \(0\)\
\-\ further\\:\\ 0\\.0680172899994144\ \(0\)\
\-\ survival\\:\\ 0\\.06794588949794435\ \(0\)\
\-\ contrast\\:\\ 0\\.06765415068465741\ \(0\)\
\-\ any\\:\\ 0\\.06749130363769901\ \(0\)\
\-\ pet\\:\\ 0\\.06447847058261841\ \(0\)\
\-\ 85\\:\\ 0\\.06421878543690736\ \(0\)\
\-\ dysphagia\\:\\ 0\\.06288160708805432\ \(0\)\
\-\ received\\:\\ 0\\.06057990063025478\ \(0\)\
\-\ that\\:\\ 0\\.06042518622786398\ \(0\)\
\-\ reflux\\:\\ 0\\.060297152662728254\ \(0\)\
\-\ cell\\:\\ 0\\.05973901647581406\ \(0\)\
\-\ evaluated\\:\\ 0\\.059486207407163295\ \(0\)\
\-\ carbamazepine\\:\\ 0\\.05566899658747052\ \(0\)\
\-\ 19th\\:\\ 0\\.05566899658747052\ \(0\)\
\-\ 1970s\\:\\ 0\\.05566899658747052\ \(0\)\
\-\ swedish\\:\\ 0\\.05566899658747052\ \(0\)\
\-\ suing\\:\\ 0\\.05566899658747052\ \(0\)\
\-\ popularity\\:\\ 0\\.05566899658747052\ \(0\)\
\-\ drawbacks\\:\\ 0\\.05566899658747052\ \(0\)\
\-\ visualizes\\:\\ 0\\.05566899658747052\ \(0\)\
\-\ metastses\\:\\ 0\\.05566899658747052\ \(0\)\
\-\ elton\\:\\ 0\\.05566899658747052\ \(0\)\
\-\ v51\\:\\ 0\\.05566899658747052\ \(0\)\
\-\ n12\\:\\ 0\\.05566899658747052\ \(0\)\
\-\ korst\\:\\ 0\\.05566899658747052\ \(0\)\
\-\ altorki\\:\\ 0\\.05566899658747052\ \(0\)\
\-\ buenaventura\\:\\ 0\\.05566899658747052\ \(0\)\
\-\ there\\:\\ 0\\.055403391211299745\ \(0\)\
\-\ us\\:\\ 0\\.055379650770966536\ \(0\)\
\-\ chest\\:\\ 0\\.055123672083866586\ \(0\)\
\-\ located\\:\\ 0\\.05507221029821567\ \(0\)\
\-\ imaging\\:\\ 0\\.05488172434952518\ \(0\)\
\-\ where\\:\\ 0\\.054713221435707504\ \(0\)\
\-\ gatroesophageal\\:\\ 0\\.05319469819190589\ \(0\)\
\-\ eus\\:\\ 0\\.05319469819190589\ \(0\)\
\-\ mass\\:\\ 0\\.05318618119711084\ \(0\)\
\-\ enhanced\\:\\ 0\\.05301002682348581\ \(0\)\
\-\ commonly\\:\\ 0\\.05151566967078856\ \(0\)\
\-\ its\\:\\ 0\\.05151566967078856\ \(0\)\
\-\ constitutes\\:\\ 0\\.05143915554208\ \(0\)\
\-\ skill\\:\\ 0\\.05143915554208\ \(0\)\
\-\ gaining\\:\\ 0\\.050077450872661064\ \(0\)\
\-\ 5yr\\:\\ 0\\.050077450872661064\ \(0\)\
\-\ patel\\:\\ 0\\.050077450872661064\ \(0\)\
\-\ lesion\\:\\ 0\\.0500662705499865\ \(0\)\
\-\ did\\:\\ 0\\.04994279921626193\ \(0\)\
\-\ iv\\:\\ 0\\.049744987083785074\ \(0\)\
\-\ malignant\\:\\ 0\\.049627820666502724\ \(0\)\
\-\ eric\\:\\ 0\\.04896485714651537\ \(0\)\
\-\ obstruction\\:\\ 0\\.048765068174991426\ \(0\)\
\-\ atenolol\\:\\ 0\\.048024172554562684\ \(0\)\
\-\ deaths\\:\\ 0\\.048024172554562684\ \(0\)\
\-\ columnar\\:\\ 0\\.048024172554562684\ \(0\)\
\-\ visualizing\\:\\ 0\\.048024172554562684\ \(0\)\
\-\ fungating\\:\\ 0\\.047209314496689476\ \(0\)\
\-\ operator\\:\\ 0\\.047209314496689476\ \(0\)\
\-\ positron\\:\\ 0\\.047209314496689476\ \(0\)\
\-\ type\\:\\ 0\\.046703949918800294\ \(0\)\
\-\ cardia\\:\\ 0\\.04649055875095074\ \(0\)\
\-\ worldwide\\:\\ 0\\.04649055875095074\ \(0\)\
\-\ steadily\\:\\ 0\\.04649055875095074\ \(0\)\
\-\ palliation\\:\\ 0\\.04649055875095074\ \(0\)\
\-\ consumption\\:\\ 0\\.04584760982727054\ \(0\)\
\-\ viewing\\:\\ 0\\.04584760982727054\ \(0\)\
\-\ hematemesis\\:\\ 0\\.04526599177862724\ \(0\)\
\-\ sh\\:\\ 0\\.04526599177862724\ \(0\)\
\-\ adjacent\\:\\ 0\\.045127881104376606\ \(0\)\
\-\ hypodensities\\:\\ 0\\.04473501610112485\ \(0\)\
\-\ reach\\:\\ 0\\.04473501610112485\ \(0\)\
\-\ candidates\\:\\ 0\\.04473501610112485\ \(0\)\
\-\ 10th\\:\\ 0\\.044246565827074515\ \(0\)\
\-\ barrett\\:\\ 0\\.044246565827074515\ \(0\)\
\-\ emission\\:\\ 0\\.044246565827074515\ \(0\)\
\-\ tool\\:\\ 0\\.04379433150917216\ \(0\)\
\-\ proximal\\:\\ 0\\.04349480511485816\ \(0\)\
\-\ weekly\\:\\ 0\\.042609519535431795\ \(0\)\
\-\ odynophagia\\:\\ 0\\.042609519535431795\ \(0\)\
\-\ providing\\:\\ 0\\.042609519535431795\ \(0\)\
\-\ abdomen\\:\\ 0\\.04247997637206033\ \(0\)\
\-\ wall\\:\\ 0\\.04235082446421601\ \(0\)\
\-\ clinicians\\:\\ 0\\.04226071770556022\ \(0\)\
\-\ for\\:\\ 0\\.04220274854948542\ \(0\)\
\-\ solids\\:\\ 0\\.04193077947865367\ \(0\)\
\-\ properly\\:\\ 0\\.04193077947865367\ \(0\)\
\-\ carcinoma\\:\\ 0\\.04164370814506699\ \(0\)\
\-\ include\\:\\ 0\\.04142343611951612\ \(0\)\
\-\ two\\:\\ 0\\.041344312721485095\ \(0\)\
\-\ 7th\\:\\ 0\\.041320033113607525\ \(0\)\
\-\ scan\\:\\ 0\\.041304942553797186\ \(0\)\
\-\ egd\\:\\ 0\\.04103615073323671\ \(0\)\
\-\ distinguished\\:\\ 0\\.04103615073323671\ \(0\)\
\-\ psh\\:\\ 0\\.040764889599764056\ \(0\)\
\-\ thirds\\:\\ 0\\.040505175055734324\ \(0\)\
\-\ interestingly\\:\\ 0\\.040505175055734324\ \(0\)\
\-\ distal\\:\\ 0\\.040451116071150164\ \(0\)\
\-\ lfts\\:\\ 0\\.040256064112461076\ \(0\)\
\-\ lining\\:\\ 0\\.040256064112461076\ \(0\)\
\-\ due\\:\\ 0\\.04001904470643678\ \(0\)\
\-\ fluids\\:\\ 0\\.04001672478168399\ \(0\)\
\-\ etoh\\:\\ 0\\.04001672478168399\ \(0\)\
\-\ epithelium\\:\\ 0\\.04001672478168399\ \(0\)\
\-\ an\\:\\ 0\\.039933845318254516\ \(0\)\
\-\ chem\\:\\ 0\\.03978641930999559\ \(0\)\
\-\ lymphatic\\:\\ 0\\.03978641930999559\ \(0\)\
\-\ hematogenous\\:\\ 0\\.03956449046378164\ \(0\)\
\-\ 6th\\:\\ 0\\.03956449046378164\ \(0\)\
\-\ overview\\:\\ 0\\.03956449046378164\ \(0\)\
\-\ gold\\:\\ 0\\.03956449046378164\ \(0\)\
\-\ evidence\\:\\ 0\\.03951657843055873\ \(0\)\
\-\ these\\:\\ 0\\.039314564305673844\ \(0\)\
\-\ patients\\:\\ 0\\.03916521822378976\ \(0\)\
\-\ more\\:\\ 0\\.038228983240674225\ \(0\)\
\-\ provides\\:\\ 0\\.0382027857943627\ \(0\)\
\-\ meds\\:\\ 0\\.0380308766601697\ \(0\)\
\-\ united\\:\\ 0\\.0380308766601697\ \(0\)\
\-\ allows\\:\\ 0\\.0380308766601697\ \(0\)\
\-\ prompt\\:\\ 0\\.03786367796287591\ \(0\)\
\-\ gastroesophageal\\:\\ 0\\.037700938433263144\ \(0\)\
\-\ circumferential\\:\\ 0\\.03738792773648949\ \(0\)\
\-\ gerd\\:\\ 0\\.03738792773648949\ \(0\)\
\-\ imaged\\:\\ 0\\.03738792773648949\ \(0\)\
\-\ modalities\\:\\ 0\\.0372372442609132\ \(0\)\
\-\ into\\:\\ 0\\.037008945361149875\ \(0\)\
\-\ obstructing\\:\\ 0\\.036806309687846185\ \(0\)\
\-\ among\\:\\ 0\\.036806309687846185\ \(0\)\
\-\ decade\\:\\ 0\\.03666917199075075\ \(0\)\
\-\ panel\\:\\ 0\\.036535048554373534\ \(0\)\
\-\ endoscopic\\:\\ 0\\.03640380971776636\ \(0\)\
\-\ distant\\:\\ 0\\.03640380971776636\ \(0\)\
\-\ was\\:\\ 0\\.036395038246421596\ \(0\)\
\-\ or\\:\\ 0\\.03632948655159871\ \(0\)\
\-\ endoscopy\\:\\ 0\\.036026223067070554\ \(0\)\
\-\ extended\\:\\ 0\\.03590538009447664\ \(0\)\
\-\ were\\:\\ 0\\.035887245576443697\ \(0\)\
\-\ organ\\:\\ 0\\.03578688373629347\ \(0\)\
\-\ black\\:\\ 0\\.03567064458941768\ \(0\)\
\-\ staging\\:\\ 0\\.035556578264605065\ \(0\)\
\-\ sensitivity\\:\\ 0\\.03533464941839111\ \(0\)\
\-\ too\\:\\ 0\\.03501619260728906\ \(0\)\
\-\ easily\\:\\ 0\\.034812761413007445\ \(0\)\
\-\ have\\:\\ 0\\.034779151476873306\ \(0\)\
\-\ htn\\:\\ 0\\.03471353368687383\ \(0\)\
\-\ directly\\:\\ 0\\.03461589367265237\ \(0\)\
\-\ mechanical\\:\\ 0\\.03451979136051791\ \(0\)\
\-\ combined\\:\\ 0\\.03451979136051791\ \(0\)\
\-\ appeared\\:\\ 0\\.03442517906687453\ \(0\)\
\-\ hard\\:\\ 0\\.03442517906687453\ \(0\)\
\-\ information\\:\\ 0\\.03442517906687453\ \(0\)\
\-\ tail\\:\\ 0\\.034332011292281556\ \(0\)\
\-\ with\\:\\ 0\\.03408130579358531\ \(0\)\
\-\ multiple\\:\\ 0\\.03405279694070157\ \(0\)\
\-\ surgical\\:\\ 0\\.03383772985317547\ \(0\)\
\-\ tomography\\:\\ 0\\.033716863649944064\ \(0\)\
\-\ glucose\\:\\ 0\\.03363383691748539\ \(0\)\
\-\ dependent\\:\\ 0\\.033551924671505924\ \(0\)\
\-\ concerning\\:\\ 0\\.03339132670032887\ \(0\)\
\-\ portal\\:\\ 0\\.03331258534072885\ \(0\)\
\-\ continues\\:\\ 0\\.03323484708307896\ \(0\)\
\-\ comparison\\:\\ 0\\.033158086691098966\ \(0\)\
\-\ remains\\:\\ 0\\.033158086691098966\ \(0\)\
\-\ 95\\:\\ 0\\.03300740321552268\ \(0\)\
\-\ advanced\\:\\ 0\\.03271675920487565\ \(0\)\
\-\ pancreas\\:\\ 0\\.03271675920487565\ \(0\)\
\-\ once\\:\\ 0\\.03271675920487565\ \(0\)\
\-\ 43\\:\\ 0\\.03257646864245566\ \(0\)\
\-\ radiologic\\:\\ 0\\.03243933094536024\ \(0\)\
\-\ abd\\:\\ 0\\.03237190074877615\ \(0\)\
\-\ types\\:\\ 0\\.03237190074877615\ \(0\)\
\-\ standard\\:\\ 0\\.03230520750898301\ \(0\)\
\-\ least\\:\\ 0\\.03217396867237584\ \(0\)\
\-\ alcohol\\:\\ 0\\.03217396867237584\ \(0\)\
\-\ extend\\:\\ 0\\.03210939271845368\ \(0\)\
\-\ thus\\:\\ 0\\.03198225539697791\ \(0\)\
\-\ overall\\:\\ 0\\.03198225539697791\ \(0\)\
\-\ resected\\:\\ 0\\.031857712896716926\ \(0\)\
\-\ has\\:\\ 0\\.03180051793144846\ \(0\)\
\-\ rounded\\:\\ 0\\.03167553904908612\ \(0\)\
\-\ invasive\\:\\ 0\\.03167553904908612\ \(0\)\
\-\ which\\:\\ 0\\.03165703658578155\ \(0\)\
\-\ higher\\:\\ 0\\.031616003252956104\ \(0\)\
\-\ pmh\\:\\ 0\\.03149864635340754\ \(0\)\
\-\ options\\:\\ 0\\.03138350386763632\ \(0\)\
\-\ replacement\\:\\ 0\\.03127049377315086\ \(0\)\
\-\ localized\\:\\ 0\\.03127049377315086\ \(0\)\
\-\ lumen\\:\\ 0\\.030996798992307992\ \(0\)\
\-\ leading\\:\\ 0\\.03094350283956407\ \(0\)\
\-\ versus\\:\\ 0\\.030786351561898538\ \(0\)\
\-\ dyspnea\\:\\ 0\\.03063314592439342\ \(0\)\
\-\ prognosis\\:\\ 0\\.03063314592439342\ \(0\)\
\-\ states\\:\\ 0\\.03058292036761692\ \(0\)\
\-\ appropriate\\:\\ 0\\.03058292036761692\ \(0\)\
\-\ current\\:\\ 0\\.03048369264148331\ \(0\)\
\-\ major\\:\\ 0\\.03043467735226109\ \(0\)\
\-\ main\\:\\ 0\\.030337812291459928\ \(0\)\
\-\ incidence\\:\\ 0\\.029965032549795604\ \(0\)\
\-\ node\\:\\ 0\\.029919996399260226\ \(0\)\
\-\ partially\\:\\ 0\\.02987529018685582\ \(0\)\
\-\ those\\:\\ 0\\.029786848483738713\ \(0\)\
\-\ subsequently\\:\\ 0\\.029699670276811214\ \(0\)\
\-\ by\\:\\ 0\\.029564811092949117\ \(0\)\
\-\ factors\\:\\ 0\\.02944536803530916\ \(0\)\
\-\ gastric\\:\\ 0\\.029322083626115398\ \(0\)\
\-\ strength\\:\\ 0\\.029161485654938344\ \(0\)\
\-\ stomach\\:\\ 0\\.02904375137864189\ \(0\)\
\-\ suspected\\:\\ 0\\.02852250059674336\ \(0\)\
\-\ near\\:\\ 0\\.02834662759706514\ \(0\)\
\-\ test\\:\\ 0\\.02831205316633391\ \(0\)\
\-\ metastases\\:\\ 0\\.028142059703385625\ \(0\)\
\-\ best\\:\\ 0\\.028009394245918678\ \(0\)\
\-\ general\\:\\ 0\\.02794412762698532\ \(0\)\
\-\ junction\\:\\ 0\\.02787955167306316\ \(0\)\
\-\ references\\:\\ 0\\.027752414351587387\ \(0\)\
\-\ stage\\:\\ 0\\.027721039625919375\ \(0\)\
\-\ rule\\:\\ 0\\.027627871851326407\ \(0\)\
\-\ especially\\:\\ 0\\.027536105149107835\ \(0\)\
\-\ appear\\:\\ 0\\.027415857500713216\ \(0\)\
\-\ presenting\\:\\ 0\\.027268805308017022\ \(0\)\
\-\ evaluate\\:\\ 0\\.02706870965396599\ \(0\)\
\-\ lymph\\:\\ 0\\.02706870965396599\ \(0\)\
\-\ made\\:\\ 0\\.026847785230550772\ \(0\)\
\-\ uptake\\:\\ 0\\.02676695794691747\ \(0\)\
\-\ use\\:\\ 0\\.02663458028961092\ \(0\)\
\-\ third\\:\\ 0\\.026505013411742905\ \(0\)\
\-\ rate\\:\\ 0\\.026378140428085287\ \(0\)\
\-\ at\\:\\ 0\\.026296463269195422\ \(0\)\
\-\ used\\:\\ 0\\.026060109269736866\ \(0\)\
\-\ about\\:\\ 0\\.026060109269736866\ \(0\)\
\-\ 40\\:\\ 0\\.025601068068027852\ \(0\)\
\-\ since\\:\\ 0\\.025215526989918635\ \(0\)\
\-\ involvement\\:\\ 0\\.025194805847089077\ \(0\)\
\-\ vein\\:\\ 0\\.024951489735004793\ \(0\)\
\-\ portion\\:\\ 0\\.024892146926673846\ \(0\)\
\-\ risk\\:\\ 0\\.024872493541892537\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.024717504367709534\ \(0\)\
\-\ then\\:\\ 0\\.024641461381224417\ \(0\)\
\-\ kidney\\:\\ 0\\.02445539908096561\ \(0\)\
\-\ involving\\:\\ 0\\.024382534087495713\ \(0\)\
\-\ weight\\:\\ 0\\.024274842397965946\ \(0\)\
\-\ new\\:\\ 0\\.024082212120943386\ \(0\)\
\-\ does\\:\\ 0\\.02406499808780802\ \(0\)\
\-\ liver\\:\\ 0\\.024013645436656992\ \(0\)\
\-\ enlarged\\:\\ 0\\.023730537911305936\ \(0\)\
\-\ cause\\:\\ 0\\.023714286581594794\ \(0\)\
\-\ size\\:\\ 0\\.02356993994012888\ \(0\)\
\-\ week\\:\\ 0\\.02341346032287897\ \(0\)\
\-\ study\\:\\ 0\\.023215856958305074\ \(0\)\
\-\ radiation\\:\\ 0\\.023068092579029326\ \(0\)\
\-\ white\\:\\ 0\\.022966746015031823\ \(0\)\
\-\ out\\:\\ 0\\.022881197361182395\ \(0\)\
\-\ patient\\:\\ 0\\.02264398391270978\ \(0\)\
\-\ found\\:\\ 0\\.02252374916189892\ \(0\)\
\-\ bowel\\:\\ 0\\.022339611937686733\ \(0\)\
\-\ show\\:\\ 0\\.022098279670673803\ \(0\)\
\-\ treated\\:\\ 0\\.021677259593207557\ \(0\)\
\-\ ultrasound\\:\\ 0\\.021471542224618057\ \(0\)\
\-\ primary\\:\\ 0\\.021404482531097134\ \(0\)\
\-\ demonstrated\\:\\ 0\\.021393377212836736\ \(0\)\
\-\ loss\\:\\ 0\\.02120761479074207\ \(0\)\
\-\ changes\\:\\ 0\\.021037798735183872\ \(0\)\
\-\ lymphoma\\:\\ 0\\.020731595506323378\ \(0\)\
\-\ through\\:\\ 0\\.020721648689614274\ \(0\)\
\-\ all\\:\\ 0\\.020721648689614274\ \(0\)\
\-\ performed\\:\\ 0\\.0205937941834647\ \(0\)\
\-\ therapy\\:\\ 0\\.020000684740232866\ \(0\)\
\-\ lesions\\:\\ 0\\.019991859907603184\ \(0\)\
\-\ low\\:\\ 0\\.019974248435927867\ \(0\)\
\-\ common\\:\\ 0\\.019741338174657733\ \(0\)\
\-\ none\\:\\ 0\\.019023522919126595\ \(0\)\
\-\ increased\\:\\ 0\\.018823669995757165\ \(0\)\
\-\ upper\\:\\ 0\\.01860200122884514\ \(0\)\
\-\ noted\\:\\ 0\\.01845628676196127\ \(0\)\
\-\ without\\:\\ 0\\.018361041584556766\ \(0\)\
\-\ associated\\:\\ 0\\.018347555676968864\ \(0\)\
\-\ tissue\\:\\ 0\\.01826061632253486\ \(0\)\
\-\ most\\:\\ 0\\.01811625243374456\ \(0\)\
\-\ diagnosis\\:\\ 0\\.018045331320961856\ \(0\)\
\-\ small\\:\\ 0\\.017956244035120007\ \(0\)\
\-\ mri\\:\\ 0\\.01786843862528328\ \(0\)\
\-\ lower\\:\\ 0\\.017788021020459167\ \(0\)\
\-\ demonstrates\\:\\ 0\\.017488237233120655\ \(0\)\
\-\ large\\:\\ 0\\.017441609531957208\ \(0\)\
\-\ but\\:\\ 0\\.017213670028883084\ \(0\)\
\-\ after\\:\\ 0\\.01688697093046715\ \(0\)\
\-\ well\\:\\ 0\\.01685524276176525\ \(0\)\
\-\ treatment\\:\\ 0\\.016581918118802906\ \(0\)\
\-\ as\\:\\ 0\\.013984469803035032\ \(0\)\
\-\ this\\:\\ 0\\.01196139195832999\ \(0\)\
\-\ left\\:\\ 0\\.011874498931252798\ \(0\)\
\-\ no\\:\\ 0\\.01131986235567024\ \(0\)\
\-\ on\\:\\ 0\\.010513260643484124\ \(0\)\
